Literature DB >> 9701455

Genetic polymorphisms and risk of coronary artery disease.

M Murata1, K Kawano, Y Matsubara, K Ishikawa, K Watanabe, Y Ikeda.   

Abstract

The fact that certain ethnic groups and specific populations residing in certain geographic areas carry an increased risk for thrombosis and that thrombosis occurs in young patients without established risk factors indicates the presence of new, previously unrecognized inherited conditions predisposing to thrombosis. We are now aware that interindividual variations within the loci coding for proteins relevant to lipid and vascular metabolisms as well as blood coagulation are universally found. Platelets play central roles in cerebrovascular diseases and acute coronary syndromes, as demonstrated by histopathological findings and clinical observations showing the efficacy of antiplatelet therapies for these disorders. In this article, we show our recent findings on the association between coronary artery disease (CAD) and polymorphisms in platelet membrane glycoproteins. The glycoprotein (GP) Ib/IX complex is a receptor for von Willebrand factor, which mediates shear stress-dependent platelet activation. It has recently been implicated in the pathogenesis of acute coronary syndromes. We have determined genotypes of the "size-polymorphism" of GPIb alpha--i.e., the variable number (1-4) of a 13 amino acid sequence (399-411)--in angiographically proven Japanese CAD patients with myocardial infarction or angina pectoris as well as in individuals from the general population with no history of angina or other heart diseases and normal resting electrocardiograms (ECG). We have found that the genotypes having at least one 4-repeat allele (4R) are more frequently found in patients than in controls. Logistic regression analyses for the adjustment of age, sex, and other acquired coronary risk factors provided an odds ratio of 7.94 (p=0.0043) for those with 4R vs. those without 4R, suggesting that the presence of 4R is an independent risk factor for CAD. The molecular mechanisms underlying this association are currently under investigation. Relationships between arterial thrombosis and polymorphisms in other platelet GPs (collagen receptor and fibrinogen receptor), blood coagulation factors, fibrinolytic factors, vasoactive substances, and factors relevant for lipid metabolisms are also discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701455     DOI: 10.1055/s-2007-995849

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  6 in total

Review 1.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

Review 2.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

3.  Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients.

Authors:  Dermot Kenny; Clare Muckian; Desmond J Fitzgerald; Christopher P Cannon; Denis C Shields
Journal:  J Thromb Thrombolysis       Date:  2002-02       Impact factor: 2.300

Review 4.  Arterial thrombus formation in cardiovascular disease.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher
Journal:  Nat Rev Cardiol       Date:  2011-07-05       Impact factor: 32.419

5.  Association between polymorphisms of platelet membrane glycoprotein Ibα and risk of coronary heart disease in Han Chinese, Henan, China.

Authors:  Jinghua Zhang; Liang Zhao; Peisheng Lv; Guizhi Liu; Weiguo Du; Fan Yang; Youyou Du; Luosha Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  Complement activation and cardiac surgery: a novel target for improving outcomes.

Authors:  Gregory L Stahl; Stanton K Shernan; Peter K Smith; Jerrold H Levy
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.